PatrickYungWenMD

Neurology • Boston, MA

Neurooncology

Professor of Neurology, Brigham and Women's Hospital

Join to view full profile

Dr. Wen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wen's full profile

Already have an account?

Office
75 Francis St
Dept of Neurology
Boston, MA 02115
Phone+1 617-732-7432

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1985 - 1988
Barts and The London SOM & DentClass of 1981

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 1988 - 2027
NH State Medical License 2024 - 2026
CT State Medical License 2022 - 2025
American Board of Psychiatry and Neurology Neurology
UCNSNeuro-Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2015
Boston Magazine Castle Connolly, 2011-2015
Super Doctor SuperDoctors.com

Clinical Trials

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma Start of enrollment: 2001 Feb 27
Completed
Phase 1, Phase 2
Imatinib Mesylate in Treating Patients With Recurrent Meningioma Start of enrollment: 2003 Feb 01
Completed
Phase 2
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma Start of enrollment: 2004 Mar 01
Completed
Phase 2
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2001 Apr 01
Completed
Phase 2
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Start of enrollment: 2005 Apr 01
Completed
Phase 1, Phase 2
Prolonged Daily Temozolomide for Low-Grade Glioma Start of enrollment: 2001 Sep 01
Completed
Phase 2
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2005 Sep 01
Completed
Phase 2
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas Start of enrollment: 2005 Dec 16
Active, not recruiting
Phase 1
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors Start of enrollment: 2007 May 25
Completed
Phase 1, Phase 2
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Start of enrollment: 2007 Oct 01
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Start of enrollment: 2007 Oct 01
Completed
Phase 2
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma Start of enrollment: 2008 Jul 01
Completed
Phase 1
Dose-Intense Temozolomide in Recurrent Glioblastoma Start of enrollment: 2008 May 01
Completed
Phase 2
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Start of enrollment: 2008 Aug 01
Unknown status
Phase 1, Phase 2
Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor Start of enrollment: 2008 Jun 01
Completed
Phase 1
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2009 Jul 10
Completed
Phase 1, Phase 2
Monthly SOM230C for Recurrent or Progressive Meningioma Start of enrollment: 2009 Mar 01
Completed
Phase 2
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma Start of enrollment: 2009 Mar 01
Completed
Phase 1, Phase 2
PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma Start of enrollment: 2010 Apr 01
Completed
Phase 2
MK-2206 for Recurrent Malignant Glioma
Withdrawn
Phase 2
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma Start of enrollment: 2011 Dec 01
Terminated
Phase 1
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
BIBF 1120 for Recurrent High-Grade Gliomas Start of enrollment: 2012 May 01
Completed
Phase 2
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2011 Dec 30
Completed
Phase 1
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L) Start of enrollment: 2011 Nov 01
Terminated
Phase 2
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2014 Feb 28
Completed
Phase 1
ANG1005 in Patients With Recurrent High-Grade Glioma Start of enrollment: 2013 Oct 01
Completed
Phase 2
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM Start of enrollment: 2013 Dec 09
Completed
Phase 2
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas Start of enrollment: 2014 Mar 03
Terminated
Phase 2
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Start of enrollment: 2018 Oct 30
Terminated
Phase 1
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma Start of enrollment: 2016 Sep 21
Completed
Phase 1
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas Start of enrollment: 2017 Oct 17
Active, not recruiting
Phase 2
Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2017 Sep 13
Completed
Phase 2
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2017 Jun 07
Terminated
Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer Start of enrollment: 2018 Apr 02
Recruiting
Phase 1
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Start of enrollment: 2019 Jul 30
Recruiting
Phase 2, Phase 3
Abemaciclib + Pembrolizumab In Glioblastoma Start of enrollment: 2021 Dec 01
Withdrawn
Phase 2
VB-111 in Surgically Accessible Recurrent/Progressive GBM Start of enrollment: 2020 Aug 01
Active, not recruiting
Phase 2
Surgical Nivolumab And Ipilimumab For Recurrent GBM Start of enrollment: 2021 Feb 01
Active, not recruiting
Phase 1
Surgical Pembro +/- Olaparib w TMZ for rGBM Start of enrollment: 2022 Oct 21
Recruiting
Phase 2
Roles: Principal Investigator, Contact, Sponsor-Investigator
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) Start of enrollment: 2023 Jan 23
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.
Veronica Rendo, Eudocia Q Lee, Connor Bossi, Nicholas Khuu, Michelle A Rudek
Science Translational Medicine. 2025-02-19
2 citations
Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1.
Martin J van den Bent, Enrico Franceschi, Mehdi Touat, Pim J French, Ahmed Idbaih
Neuro-Oncology. 2025-02-10
Identifying appropriate external control datasets in support of future glioblastoma clinical trials leveraging external data.
Rifaquat Rahman, Steffen Ventz, Robert Redd, Geoffrey Fell, Yujue Tan
Neuro-Oncology. 2025-02-08

Other

Anticoagulant and antiplatelet therapy in patients with brain tumors
Wen PY, Lee EQ
http://www.uptodate.com/contents/anticoagulant-and-antiplatelet-therapy-in-patients-with-brain-tumor
UpToDate, Wolters Kluwer Health - 2013-02-22
Uncommon brain tumors
Wen PY, Norden AD, Chheda MG
http://www.uptodate.com/contents/uncommon-brain-tumors
UpToDate, Wolters Kluwer Health - 2013-02-28
Systemic treatment of recurrent meningioma
Wen PY
http://www.uptodate.com/contents/systemic-treatment-of-recurrent-meningioma
UpToDate, Wolters Kluwer Health - 2013-01-03
Neurologic complications of cancer treatment with biologic agents
Wen PY, Lee EQ
http://www.uptodate.com/contents/neurologic-complications-of-cancer-treatment-with-biologic-agents
UpToDate, Wolters Kluwer Health - 2013-02-25
Neurologic complications of non-platinum cancer chemotherapy
Wen PY, Lee EQ
http://www.uptodate.com/contents/neurologic-complications-of-non-platinum-cancer-chemotherapy
UpToDate, Wolters Kluwer Health - 2013-03-19
Neurologic complications of platinum-based chemotherapy
Wen PY, Lee EQ
http://www.uptodate.com/contents/neurologic-complications-of-platinum-based-chemotherapy
UpToDate, Wolters Kluwer Health - 2012-12-21
Seizures in patients with primary and metastatic brain tumors
Wen PY, Avila EK, Drappatz J
http://www.uptodate.com/contents/seizures-in-patients-with-primary-and-metastatic-brain-tumors
UpToDate, Wolters Kluwer Health - 2013-04-03
Management of vasogenic edema in patients with primary and metastatic brain tumors
Wen PY, Drappatz J
http://www.uptodate.com/contents/management-of-vasogenic-edema-in-patients-with-primary-and-metastat
UpToDate, Wolters Kluwer Health - 2013-02-13
Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases
Wen PY, Loeffler JS
http://www.uptodate.com/contents/overview-of-the-clinical-manifestations-diagnosis-and-management-of
UpToDate, Wolters Kluwer Health - 2012-09-28
Systemic therapy for brain metastases
Wen PY, Drappatz J
http://www.uptodate.com/contents/systemic-therapy-for-brain-metastases
UpToDate, Wolters Kluwer Health - 2012-12-07
Treatment of brain metastases in favorable prognosis patients
Wen PY, Loeffler JS
http://www.uptodate.com/contents/treatment-of-brain-metastases-in-favorable-prognosis-patients
UpToDate, Wolters Kluwer Health - 2012-12-24
Treatment of brain metastases in poor prognosis patients
Wen PY, Loeffler JS
http://www.uptodate.com/contents/treatment-of-brain-metastases-in-poor-prognosis-patients
UpToDate, Wolters Kluwer Health - 2012-12-21
Assessment of disease status and surveillance after treatment in patients with brain tumors
Wen PY
http://www.uptodate.com/contents/assessment-of-disease-status-and-surveillance-after-treatment-in-pa
UpToDate, Wolters Kluwer Health - 2013-01-19
Join now to see all

Press Mentions

Global Coalition for Adaptive Research Announces Evaluation of AZD1390 in GBM AGILE TrialNovember 23rd, 2024
Clinical Trials Show Promise in Treating Central Nervous System Lymphoma, Breast Cancer and GlioblastomaJuly 15th, 2024
Solving the Brain Riddle: New Treatments for Brain TumorsMay 22nd, 2024
Join now to see all

Grant Support

Therapeutics Studies Of Primary CNS MalignanciesNational Cancer Institute2000–2008
Immunotherapy For Malignant GliomasNational Cancer Institute1990–1994